WO2009040073A3 - Use of a peptide as a therapeutic agent - Google Patents
Use of a peptide as a therapeutic agent Download PDFInfo
- Publication number
- WO2009040073A3 WO2009040073A3 PCT/EP2008/007944 EP2008007944W WO2009040073A3 WO 2009040073 A3 WO2009040073 A3 WO 2009040073A3 EP 2008007944 W EP2008007944 W EP 2008007944W WO 2009040073 A3 WO2009040073 A3 WO 2009040073A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glu
- diseases
- ala
- pro
- phe
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/35—Corticotropin [ACTH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The present invention is directed to the use of the peptide compound Arg-Pro-Val-Lys- Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala- Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07017762 | 2007-09-11 | ||
EP07017762.1 | 2007-09-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009040073A2 WO2009040073A2 (en) | 2009-04-02 |
WO2009040073A3 true WO2009040073A3 (en) | 2009-05-22 |
Family
ID=40336638
Family Applications (11)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/007601 WO2009040005A2 (en) | 2007-09-11 | 2008-09-09 | Use of the peptide rfmwmr as a therapeutic agent |
PCT/EP2008/007971 WO2009033787A2 (en) | 2007-09-11 | 2008-09-09 | Use of a peptide as a therapeutic agent |
PCT/EP2008/007647 WO2009043467A1 (en) | 2007-09-11 | 2008-09-09 | U e of urocortin and corticotropin-releasing fact r as therapeutic agents |
PCT/EP2008/007943 WO2009040072A2 (en) | 2007-09-11 | 2008-09-09 | Use of a peptide as a therapeutic agent |
PCT/EP2008/007636 WO2009043456A2 (en) | 2007-09-11 | 2008-09-09 | Use of a peptide as a therapeutic agent |
PCT/EP2008/007741 WO2009040032A2 (en) | 2007-09-11 | 2008-09-09 | Use of a peptide as a therapeutic agent |
PCT/EP2008/007793 WO2009033745A2 (en) | 2007-09-11 | 2008-09-09 | Use of a peptide as a therapeutic agent |
PCT/EP2008/007510 WO2009039968A2 (en) | 2007-09-11 | 2008-09-09 | Use of a peptide as a therapeutic agent |
PCT/EP2008/007944 WO2009040073A2 (en) | 2007-09-11 | 2008-09-09 | Use of a peptide as a therapeutic agent |
PCT/EP2008/007437 WO2009039957A2 (en) | 2007-09-11 | 2008-09-09 | Use of a peptide as a therapeutic agent |
PCT/EP2008/007811 WO2009040051A2 (en) | 2007-09-11 | 2008-09-09 | Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent |
Family Applications Before (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/007601 WO2009040005A2 (en) | 2007-09-11 | 2008-09-09 | Use of the peptide rfmwmr as a therapeutic agent |
PCT/EP2008/007971 WO2009033787A2 (en) | 2007-09-11 | 2008-09-09 | Use of a peptide as a therapeutic agent |
PCT/EP2008/007647 WO2009043467A1 (en) | 2007-09-11 | 2008-09-09 | U e of urocortin and corticotropin-releasing fact r as therapeutic agents |
PCT/EP2008/007943 WO2009040072A2 (en) | 2007-09-11 | 2008-09-09 | Use of a peptide as a therapeutic agent |
PCT/EP2008/007636 WO2009043456A2 (en) | 2007-09-11 | 2008-09-09 | Use of a peptide as a therapeutic agent |
PCT/EP2008/007741 WO2009040032A2 (en) | 2007-09-11 | 2008-09-09 | Use of a peptide as a therapeutic agent |
PCT/EP2008/007793 WO2009033745A2 (en) | 2007-09-11 | 2008-09-09 | Use of a peptide as a therapeutic agent |
PCT/EP2008/007510 WO2009039968A2 (en) | 2007-09-11 | 2008-09-09 | Use of a peptide as a therapeutic agent |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/007437 WO2009039957A2 (en) | 2007-09-11 | 2008-09-09 | Use of a peptide as a therapeutic agent |
PCT/EP2008/007811 WO2009040051A2 (en) | 2007-09-11 | 2008-09-09 | Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent |
Country Status (8)
Country | Link |
---|---|
US (4) | US20100204131A1 (en) |
EP (4) | EP2187913B1 (en) |
JP (4) | JP5385281B2 (en) |
KR (4) | KR20100056514A (en) |
AU (4) | AU2008303869A1 (en) |
CA (4) | CA2699069A1 (en) |
RU (4) | RU2010113998A (en) |
WO (11) | WO2009040005A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9192522B2 (en) | 2003-05-02 | 2015-11-24 | Eveready Battery Company, Inc. | Tampon assembly having shaped pledget |
US8796416B1 (en) * | 2010-10-25 | 2014-08-05 | Questcor Pharmaceuticals, Inc | ACTH prophylactic treatment of renal disorders |
DE102012004589A1 (en) * | 2012-03-09 | 2013-09-12 | Forschungszentrum Jülich GmbH | New angiotensin II-receptor agonist, useful for treating neurodegenerative diseases, preferably Alzheimer's dementia, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis |
WO2014021942A1 (en) * | 2012-08-01 | 2014-02-06 | University Of Southern California | Methods for limiting development of neurodegeneration |
WO2014130581A1 (en) * | 2013-02-20 | 2014-08-28 | Questcor Pharmaceuticals, Inc. | Acth for treatment of migraine headache |
US10232018B2 (en) * | 2013-03-14 | 2019-03-19 | Mallinckrodt Ard Ip Limited | ACTH for treatment of acute respiratory distress syndrome |
CN105451554B (en) | 2013-03-15 | 2019-06-11 | 南加利福尼亚大学 | For treating method, compound and the composition of angiotensins related disease |
CA2902619A1 (en) * | 2013-03-15 | 2014-09-25 | University Of Southern California | Methods for treating multiple sclerosis |
CN104277105B (en) * | 2013-07-12 | 2017-12-12 | 国家纳米科学中心 | Suppress amyloid beta aggregation and peptide inhibitor and its application of toxicity |
WO2016153558A1 (en) * | 2015-03-20 | 2016-09-29 | Atkinson Arthur J | Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps |
JP2019533661A (en) * | 2016-10-06 | 2019-11-21 | マトケ・ホールディングス・リミテッド | Antimicrobial composition |
WO2023044487A1 (en) * | 2021-09-17 | 2023-03-23 | Peptilogics, Inc. | Treatment of lung disease or injury using engineered antimicrobial peptides |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033955A1 (en) * | 2002-05-21 | 2004-02-19 | Catania Anna P. | Treatment of ophthalmic infections using antimicrobial peptides |
EP1586309A1 (en) * | 2000-09-21 | 2005-10-19 | Atrix Laboratories, Inc. | Polymeric delivery formulations of leuprolide with improved efficacy |
WO2006119388A2 (en) * | 2005-05-03 | 2006-11-09 | Novetide, Ltd. | Methods for the production of peptide having a c-terminal amide |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US447471A (en) | 1891-03-03 | John f | ||
US4188373A (en) | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4100271A (en) | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4235988A (en) | 1976-12-13 | 1980-11-25 | Imperial Chemical Industries Limited | Delivery means for biologically active agents |
US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4474753A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Topical drug delivery system utilizing thermosetting gels |
US4801612A (en) * | 1986-07-03 | 1989-01-31 | Regents Of The University Of California | Method of inhibiting inflammatory response |
US5015629A (en) * | 1989-06-26 | 1991-05-14 | University Of Southern California | Tissue repair |
US5256396A (en) | 1990-01-24 | 1993-10-26 | Colgate-Palmolive Company | Topical composition |
DK0558671T3 (en) * | 1990-11-21 | 1999-09-13 | Iterex Pharma Lp | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
DE4110422A1 (en) * | 1991-03-29 | 1992-10-01 | Bissendorf Peptide Gmbh | MEDICINE CONTAINING HUMANESE CORTICOTROPIN RELEASING HORMON (CRH) AND / OR THEIR DERIVATIVES AND / OR GLUCOCORTICOIDS OF NATURAL AND / OR SYNTHETIC PROVENANCE |
ATE160486T1 (en) | 1991-08-12 | 1997-12-15 | Nestle Sa | FOOD COMPOSITION |
PT730465E (en) * | 1993-09-24 | 2002-06-28 | Univ Southern California | UTILIZATION OF ANGIOTENSIN III AND ANALOGS OF THIS IN TISSUE SCISSORING |
AU6277796A (en) * | 1995-06-13 | 1997-01-15 | Salk Institute For Biological Studies, The | Urocortin peptides |
EA000900B1 (en) | 1996-02-19 | 2000-06-26 | Никомед Имеджинг Ас | Thermally stabilized contrast agent |
US5869450A (en) * | 1996-03-06 | 1999-02-09 | The Regents Of The University Of California | Anti-inflammatory compositions and method with corticotropin-releasing factor analogs |
TW360501B (en) | 1996-06-27 | 1999-06-11 | Nestle Sa | Dietetically balanced milk product |
DE69608801T2 (en) | 1996-09-24 | 2000-10-12 | Nestle Sa | Milk replacement product and process for its manufacture |
CA2319701C (en) * | 1998-02-09 | 2009-09-29 | University Of Southern California | Method of promoting erythropoiesis |
DE69919019T2 (en) | 1998-11-24 | 2004-11-25 | Société des Produits Nestlé S.A. | Process for the preparation of a protein composition and a baby food containing the same |
US6319900B1 (en) * | 1999-09-21 | 2001-11-20 | The Regents Of The University Of California | Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs |
AU7697500A (en) * | 1999-09-29 | 2001-04-30 | Margret Arnadottir | Acth treatment of steroid- and statin-treated patients |
EP1272209A1 (en) * | 2000-03-31 | 2003-01-08 | Aventis Pharmaceuticals Products Inc. | Use of crf receptor agonists for the treatment or prophylaxis of diseases, for example neurodegenerative diseases |
DE60128572T2 (en) | 2001-11-23 | 2008-02-07 | Société des Produits Nestlé S.A. | Process for the preparation of milk powder and concentrated milk products |
AU2003285200A1 (en) * | 2002-11-09 | 2004-06-03 | Nobex Corporation | Modified carbamate-containing prodrugs and methods of synthesizing same |
US20070053954A1 (en) * | 2003-10-24 | 2007-03-08 | Rowe Stephen C | Macromer-melt formulations |
WO2005118624A1 (en) * | 2004-06-01 | 2005-12-15 | Council Of Scientific & Industrial Research | Peptides antagonists for inhibiting heat shock protein (hsp 16.3) of mycobacterium tuberculosis |
JP2008505878A (en) * | 2004-07-08 | 2008-02-28 | エイムスコ・リミテッド | Medicine |
EP1814574A4 (en) * | 2004-10-27 | 2009-08-05 | Univ Denver | Adrenocorticotropic hormone analogs and related methods |
JP2009500401A (en) * | 2005-07-07 | 2009-01-08 | ポステック ファンデーション | Sugar absorption regulator and pharmaceutical composition |
JP5678359B2 (en) | 2006-03-10 | 2015-03-04 | ラボスイス アーゲー | Method of solubilizing, dispersing and stabilizing substances, products produced by the method and use thereof |
WO2009043504A2 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
JP2010539053A (en) * | 2007-09-11 | 2010-12-16 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | Γ1MSH as a therapeutic agent used alone or in combination with pentagastrin |
-
2008
- 2008-09-09 RU RU2010113998/15A patent/RU2010113998A/en not_active Application Discontinuation
- 2008-09-09 EP EP08802152A patent/EP2187913B1/en not_active Not-in-force
- 2008-09-09 US US12/677,519 patent/US20100204131A1/en not_active Abandoned
- 2008-09-09 US US12/677,290 patent/US8338380B2/en not_active Expired - Fee Related
- 2008-09-09 EP EP08785857A patent/EP2197465A2/en not_active Withdrawn
- 2008-09-09 JP JP2010523387A patent/JP5385281B2/en not_active Expired - Fee Related
- 2008-09-09 KR KR1020107005619A patent/KR20100056514A/en not_active Application Discontinuation
- 2008-09-09 US US12/677,303 patent/US20100210533A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005610A patent/KR20100058552A/en not_active Application Discontinuation
- 2008-09-09 CA CA2699069A patent/CA2699069A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005591A patent/KR20100057047A/en not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007601 patent/WO2009040005A2/en active Application Filing
- 2008-09-09 JP JP2010523351A patent/JP2010538980A/en active Pending
- 2008-09-09 AU AU2008303869A patent/AU2008303869A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007971 patent/WO2009033787A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007647 patent/WO2009043467A1/en active Application Filing
- 2008-09-09 AU AU2008303896A patent/AU2008303896A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007943 patent/WO2009040072A2/en active Application Filing
- 2008-09-09 US US12/676,932 patent/US20100197604A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007636 patent/WO2009043456A2/en active Application Filing
- 2008-09-09 CA CA2698751A patent/CA2698751A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007741 patent/WO2009040032A2/en active Application Filing
- 2008-09-09 KR KR1020107005639A patent/KR20100056518A/en not_active Application Discontinuation
- 2008-09-09 AU AU2008306272A patent/AU2008306272A1/en not_active Abandoned
- 2008-09-09 AU AU2008303919A patent/AU2008303919A1/en not_active Abandoned
- 2008-09-09 EP EP08802270A patent/EP2190465A2/en not_active Withdrawn
- 2008-09-09 JP JP2010523394A patent/JP5385283B2/en not_active Expired - Fee Related
- 2008-09-09 CA CA2698673A patent/CA2698673A1/en not_active Abandoned
- 2008-09-09 RU RU2010114006/15A patent/RU2010114006A/en not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007793 patent/WO2009033745A2/en active Application Filing
- 2008-09-09 CA CA2699109A patent/CA2699109A1/en not_active Abandoned
- 2008-09-09 EP EP08802191A patent/EP2187940B1/en not_active Not-in-force
- 2008-09-09 WO PCT/EP2008/007510 patent/WO2009039968A2/en active Application Filing
- 2008-09-09 RU RU2010114028/15A patent/RU2010114028A/en not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007944 patent/WO2009040073A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007437 patent/WO2009039957A2/en active Application Filing
- 2008-09-09 RU RU2010113992/15A patent/RU2010113992A/en not_active Application Discontinuation
- 2008-09-09 JP JP2010523408A patent/JP2010539035A/en active Pending
- 2008-09-09 WO PCT/EP2008/007811 patent/WO2009040051A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1586309A1 (en) * | 2000-09-21 | 2005-10-19 | Atrix Laboratories, Inc. | Polymeric delivery formulations of leuprolide with improved efficacy |
US20040033955A1 (en) * | 2002-05-21 | 2004-02-19 | Catania Anna P. | Treatment of ophthalmic infections using antimicrobial peptides |
WO2006119388A2 (en) * | 2005-05-03 | 2006-11-09 | Novetide, Ltd. | Methods for the production of peptide having a c-terminal amide |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009033734A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009033740A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009033796A8 (en) | Use of a peptide as a therapeutic agent | |
WO2009043506A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009043507A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009033805A3 (en) | Use of somatostatin-14 as a therapeutic agent | |
WO2009033717A3 (en) | Use of gonadorelin as a therapeutic agent | |
WO2009040004A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009033733A3 (en) | Use of apeptide as a therapeutic agent | |
WO2009039973A3 (en) | Use of peptide arg-asn-ile-ala-glu-ile-ile-lys-asp-ile-oh or its combination with the peptide asp-arg-gly-asp-ser-oh as a therapeutic agent | |
WO2009040021A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009033767A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009033741A3 (en) | Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s) | |
WO2009033714A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009039976A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009040073A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009039986A3 (en) | Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent | |
WO2009033754A8 (en) | Use of a peptide as a therapeutic agent | |
WO2009033786A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009043469A3 (en) | Use of pneumadin as a therapeutic agent | |
WO2009040067A3 (en) | Use of a peptide as a therapeutic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08802446 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 203858 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08802446 Country of ref document: EP Kind code of ref document: A2 |